Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2026 08:00 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

Aardvark Therapeutics announced a Phase 3 HERO trial protocol amendment expanding eligibility for patients with Prader-Willi Syndrome.